Katherine A. High
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine A. High has a total of 766 co-authors. Here are the top co-authors by number of shared publications:
Federico Mingozzi
Spark Therapeutics, Philadelphia, PA, USA
28 shared publicationsShangzhen Zhou
Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
23 shared publicationsValder R. Arruda
12 shared publications- Xavier M. Anguela
Autonomous University of Barcelona
12 shared publications Roland W. Herzog
Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine Gainesville, FL, USA
10 shared publicationsEtiena Basner-Tschakarjan
Center of Molecular and Cellular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
9 shared publications
Latest Publications
- 21 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 3951
Turning genes into medicines
- 21 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 3951
Turning genes into medicines
- Open Access
- 18 November 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (12) , 2415-2431
Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans
Optogenetics has transformed basic research on neural circuitry, led to diverse experimental insights into human brain function and dysfunction, and opened pathways for clinical translation based on new understanding of how specific cell types contribute to cognition and behavior. Many of these translational pathways do not rely on the direct application of optogenetics in humans, but rather develop and advance other treatment modalities by leveraging causal knowledge derived from optogenetic circuit neuroscience. However, a recent proof-of-principle study—showing that optogenetics applied directly to the human central nervous system can treat blindness—underscores not only the curative potential but also the need for careful ethical consideration in the extension of direct optogenetic intervention to other disorders. Here, we review relevant considerations—including the selection of clinical indications, identification of molecular and optical strategies for specificity, and navigation of safety and regulatory issues—that together inform the development of optogenetic translation targeting cells and circuits that have been causally implicated through optogenetic discoveries.
- 18 November 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (12) , 2415-2431
Open AccessRoadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans
Optogenetics has transformed basic research on neural circuitry, led to diverse experimental insights into human brain function and dysfunction, and opened pathways for clinical translation based on new understanding of how specific cell types contribute to cognition and behavior. Many of these translational pathways do not rely on the direct application of optogenetics in humans, but rather develop and advance other treatment modalities by leveraging causal knowledge derived from optogenetic circuit neuroscience. However, a recent proof-of-principle study—showing that optogenetics applied directly to the human central nervous system can treat blindness—underscores not only the curative potential but also the need for careful ethical consideration in the extension of direct optogenetic intervention to other disorders. Here, we review relevant considerations—including the selection of clinical indications, identification of molecular and optical strategies for specificity, and navigation of safety and regulatory issues—that together inform the development of optogenetic translation targeting cells and circuits that have been causally implicated through optogenetic discoveries.
- Top Cited PapersOpen Access
- 27 March 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2015-2034
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
- 27 March 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2015-2034
Top Cited PapersOpen AccessGene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
- Open Access
- 25 January 2025
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 33 (1) , 101423
Validation of a quantitative cell-based relative potency assay for LUXTURNA
- 25 January 2025
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 33 (1) , 101423
Open AccessValidation of a quantitative cell-based relative potency assay for LUXTURNA
- Top Cited PapersOpen Access
- 9 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (7) , 1796-1803
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies. The most common adverse reactions included liver enzyme elevation, headache, flu-like symptoms, infusion-related reactions, creatine kinase elevation, malaise, and fatigue; these were mostly transient. One participant had hepatocellular carcinoma on a study-mandated liver ultrasound conducted 1 year after vector infusion; molecular analysis of the resected tumor showed no evidence of vector-related insertional mutagenesis as the etiology. A remarkable 96% of participants in the phase 3 trial were able to stop factor IX (FIX) prophylaxis, with the study demonstrating noninferiority to FIX prophylaxis in terms of the primary end point, annualized bleeding rate. Key secondary end points such as the annualized infusion rate, which declined by 97%, and the plasma FIX activity level at 18 months after infusion, with least squares mean increase of 34.3 percentage points compared with baseline, were both clinically and statistically significant. The FDA’s landmark approval of Hemgenix as a pioneering treatment for hemophilia stands on the shoulders of >20 years of gene therapy clinical research and heralds a promising future for genomic medicines.
- 9 April 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (7) , 1796-1803
Top Cited PapersOpen AccessHemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
The US Food and Drug Administration (FDA)’s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies. The most common adverse reactions included liver enzyme elevation, headache, flu-like symptoms, infusion-related reactions, creatine kinase elevation, malaise, and fatigue; these were mostly transient. One participant had hepatocellular carcinoma on a study-mandated liver ultrasound conducted 1 year after vector infusion; molecular analysis of the resected tumor showed no evidence of vector-related insertional mutagenesis as the etiology. A remarkable 96% of participants in the phase 3 trial were able to stop factor IX (FIX) prophylaxis, with the study demonstrating noninferiority to FIX prophylaxis in terms of the primary end point, annualized bleeding rate. Key secondary end points such as the annualized infusion rate, which declined by 97%, and the plasma FIX activity level at 18 months after infusion, with least squares mean increase of 34.3 percentage points compared with baseline, were both clinically and statistically significant. The FDA’s landmark approval of Hemgenix as a pioneering treatment for hemophilia stands on the shoulders of >20 years of gene therapy clinical research and heralds a promising future for genomic medicines.
- Open Access
- 19 December 2023
- Published by Elsevier in Molecular Therapy
- Vol. 32 (1) , 3-4
Gene and cell therapy in 2023: Rich pipeline, slimming resources?
- 19 December 2023
- Published by Elsevier in Molecular Therapy
- Vol. 32 (1) , 3-4
Open AccessGene and cell therapy in 2023: Rich pipeline, slimming resources?
- 1 January 2023
- Vol. 133, 204-233
THE JEREMIAH METZGER LECTURE: TURNING GENES INTO MEDICINES: HIGHLIGHTS AND HURDLES IN THE DEVELOPMENT OF GENE THERAPY FOR GENETIC DISEASE.
The journey from in vitro transfer of genes into mammalian cells to approved gene therapy products has spanned decades. This manuscript summarizes hurdles encountered and obstacles overcome in the development of successful adeno-associated viral (AAV) vectors for hemophilia B and for an inherited retinal dystrophy caused by mutations in the RPE65 gene. In the case of hemophilia B, careful analysis of the first unsuccessful attempts led to the realization that the human immune response to AAV vectors was preventing durable expression; elucidation of the response to the recombinant virion led to strategies that enabled successful long-lasting gene transfer. For RPE65 deficiency, a key to success was development and validation of a novel clinical endpoint for a disease that previously lacked a pharmacologic treatment.
- 1 January 2023
- Vol. 133, 204-233
THE JEREMIAH METZGER LECTURE: TURNING GENES INTO MEDICINES: HIGHLIGHTS AND HURDLES IN THE DEVELOPMENT OF GENE THERAPY FOR GENETIC DISEASE.
The journey from in vitro transfer of genes into mammalian cells to approved gene therapy products has spanned decades. This manuscript summarizes hurdles encountered and obstacles overcome in the development of successful adeno-associated viral (AAV) vectors for hemophilia B and for an inherited retinal dystrophy caused by mutations in the RPE65 gene. In the case of hemophilia B, careful analysis of the first unsuccessful attempts led to the realization that the human immune response to AAV vectors was preventing durable expression; elucidation of the response to the recombinant virion led to strategies that enabled successful long-lasting gene transfer. For RPE65 deficiency, a key to success was development and validation of a novel clinical endpoint for a disease that previously lacked a pharmacologic treatment.
- Open Access
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A37.3-A38
89 Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease
Goal To determine whether ambulatory navigation, light sensitivity, and visual field (VF) improvements 1 year after voretigene neparvovec (VN) administration in patients with biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD) are maintained at 5 years and review safety outcomes over the entire period. Methods This is an open label, randomized, controlled Phase III trial performed at 2 sites in the United States. Patients were randomized to either original intervention (OI: bilateral subretinal VN at baseline; n=20) or delayed intervention (DI: VN after 1 year; n=9). The primary endpoint was bilateral performance on the Multi-Luminance Mobility Test (MLMT) at 7 standard light levels as measured by a change in score. Additional endpoints were full-field light sensitivity threshold (FST) testing, visual acuity (VA), and Goldmann kinetic VF (GVF), each averaged over both eyes. Safety outcomes included adverse event reporting, laboratory testing, and changes in physical and ophthalmic examinations. Results For OI patients at Year 5 (n=18) and DI patients at Year 4 (n=8), the mean (standard deviation) MLMT bilateral light level score change was 1.6 (1.1) and 2.4 (1.5) levels, respectively, compared with baseline. Subsequent to the 1-year outcomes, a change of 1 light level occurred in 6 patients (none were below pre-treatment performance) and no change in the remaining 20 (N=26). Mean change in white light FST in log10 (cd.s/m2) averaged over both eyes was −2.02 (1.45) log10 at Year 5 for OI patients (n=17) and −2.58 (1.04) log10 at Year 4 for DI patients (n=8). Mean change in VA (Holladay Scale) averaged over both eyes (logMAR was −0.00 (0.64) at Year 5 for OI patients (n=18) and −0.06 (0.26) at Year 4 for DI patients (n=8). Mean change in GVF III4e sum total degrees averaged over both eyes was 166.6 (208.7) at Year 5 for OI patients (n=15) and 178.8 (241.9) at Year 4 for DI patients (n=8). Five years after treatment, the safety profile (N=29) was consistent with vitrectomy and subretinal injection procedure with 2 reports of cataract, 1 of ptosis, and 1 new report of retinal detachment since the last update. No deleterious immune responses were reported. Conclusion Improvements in ambulatory navigation, light sensitivity, and VF are maintained for at least 5 years after VN administration in most OI patients. Improvements in DI patients were consistent with those observed in OI patients. The safety profile of VN is consistent with the administration procedure.
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A37.3-A38
Open Access89 Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease
Goal To determine whether ambulatory navigation, light sensitivity, and visual field (VF) improvements 1 year after voretigene neparvovec (VN) administration in patients with biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD) are maintained at 5 years and review safety outcomes over the entire period. Methods This is an open label, randomized, controlled Phase III trial performed at 2 sites in the United States. Patients were randomized to either original intervention (OI: bilateral subretinal VN at baseline; n=20) or delayed intervention (DI: VN after 1 year; n=9). The primary endpoint was bilateral performance on the Multi-Luminance Mobility Test (MLMT) at 7 standard light levels as measured by a change in score. Additional endpoints were full-field light sensitivity threshold (FST) testing, visual acuity (VA), and Goldmann kinetic VF (GVF), each averaged over both eyes. Safety outcomes included adverse event reporting, laboratory testing, and changes in physical and ophthalmic examinations. Results For OI patients at Year 5 (n=18) and DI patients at Year 4 (n=8), the mean (standard deviation) MLMT bilateral light level score change was 1.6 (1.1) and 2.4 (1.5) levels, respectively, compared with baseline. Subsequent to the 1-year outcomes, a change of 1 light level occurred in 6 patients (none were below pre-treatment performance) and no change in the remaining 20 (N=26). Mean change in white light FST in log10 (cd.s/m2) averaged over both eyes was −2.02 (1.45) log10 at Year 5 for OI patients (n=17) and −2.58 (1.04) log10 at Year 4 for DI patients (n=8). Mean change in VA (Holladay Scale) averaged over both eyes (logMAR was −0.00 (0.64) at Year 5 for OI patients (n=18) and −0.06 (0.26) at Year 4 for DI patients (n=8). Mean change in GVF III4e sum total degrees averaged over both eyes was 166.6 (208.7) at Year 5 for OI patients (n=15) and 178.8 (241.9) at Year 4 for DI patients (n=8). Five years after treatment, the safety profile (N=29) was consistent with vitrectomy and subretinal injection procedure with 2 reports of cataract, 1 of ptosis, and 1 new report of retinal detachment since the last update. No deleterious immune responses were reported. Conclusion Improvements in ambulatory navigation, light sensitivity, and VF are maintained for at least 5 years after VN administration in most OI patients. Improvements in DI patients were consistent with those observed in OI patients. The safety profile of VN is consistent with the administration procedure.
- Open Access
- 16 November 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-4
Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?
Gene and cell therapy products approved over the past decade in Europe and North America have provided new therapeutic options for single gene disorders and for hematologic malignancies. Lessons learned, and limitations identified, are reviewed.
- 16 November 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-4
Open AccessTurning genes into medicines—what have we learned from gene therapy drug development in the past decade?
Gene and cell therapy products approved over the past decade in Europe and North America have provided new therapeutic options for single gene disorders and for hematologic malignancies. Lessons learned, and limitations identified, are reviewed.
- Open Access
- 1 September 2020
- Published by Elsevier in Molecular Therapy
- Vol. 28 (9) , 2073-2082
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
- 1 September 2020
- Published by Elsevier in Molecular Therapy
- Vol. 28 (9) , 2073-2082
Open AccessLong-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B